Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients

Affiliations

• ¹ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
• ² Respiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang, Anhui 230000, People's Republic of China.
• ³ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People's Republic of China.
• ⁴ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui 230000, People's Republic of China.
• ⁵ Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, Anhui 230000, People's Republic of China.
• ⁶ Intensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui 230000, People's Republic of China.
• ⁷ Hemodialysis Center, Anhui Fuyang Second People's Hospital, Fuyang, Anhui 236000, People's Republic of China.
• ⁸ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.